430 related articles for article (PubMed ID: 10623666)
1. p53 mutations and expression in breast carcinoma in situ.
Lukas J; Niu N; Press MF
Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
[TBL] [Abstract][Full Text] [Related]
2. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of p53 alterations throughout breast cancer progression.
Davidoff AM; Kerns BJ; Iglehart JD; Marks JR
Cancer Res; 1991 May; 51(10):2605-10. PubMed ID: 1850660
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
7. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium.
Lukas J; Groshen S; Saffari B; Niu N; Reles A; Wen WH; Felix J; Jones LA; Hall FL; Press MF
Am J Pathol; 1997 Jan; 150(1):167-75. PubMed ID: 9006333
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Machtens S; Werner M; Jonas U
Cancer; 1996 Nov; 78(9):1958-66. PubMed ID: 8909317
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
10. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma.
Visscher DW; Sarkar FH; Shimoyama RK; Crissman JD
Diagn Mol Pathol; 1996 Sep; 5(3):187-93. PubMed ID: 8866232
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis.
Ito S; Ohga T; Saeki H; Nakamura T; Watanabe M; Tanaka S; Kakeji Y; Maehara Y
Int J Cancer; 2005 Jan; 113(1):22-8. PubMed ID: 15386362
[TBL] [Abstract][Full Text] [Related]
12. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
13. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer].
Fan P; Wu Z; Cha X; Wang X; Wang S
Zhonghua Wai Ke Za Zhi; 1998 Nov; 36(11):655-7. PubMed ID: 11825490
[TBL] [Abstract][Full Text] [Related]
15. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease.
Eriksson ET; Schimmelpenning H; Aspenblad U; Zetterberg A; Auer GU
Hum Pathol; 1994 Nov; 25(11):1228-33. PubMed ID: 7959668
[TBL] [Abstract][Full Text] [Related]
17. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components.
Lien HC; Lin CW; Mao TL; Kuo SH; Hsiao CH; Huang CS
J Pathol; 2004 Oct; 204(2):131-9. PubMed ID: 15376261
[TBL] [Abstract][Full Text] [Related]
18. The role of p53 mutations in bilateral breast carcinoma.
Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
[TBL] [Abstract][Full Text] [Related]
19. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
20. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis.
Bennett WP; Hollstein MC; Metcalf RA; Welsh JA; He A; Zhu SM; Kusters I; Resau JH; Trump BF; Lane DP
Cancer Res; 1992 Nov; 52(21):6092-7. PubMed ID: 1394236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
